• Je něco špatně v tomto záznamu ?

Long-term survival outcomes of patients with Niemann-Pick disease type C receiving miglustat treatment: A large retrospective observational study

MC. Patterson, WS. Garver, R. Giugliani, J. Imrie, H. Jahnova, FJ. Meaney, Y. Nadjar, MT. Vanier, P. Moneuse, O. Morand, D. Rosenberg, B. Schwierin, B. Héron

. 2020 ; 43 (5) : 1060-1069. [pub] 20200508

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, pozorovací studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22004859

Miglustat has been indicated for the treatment of Niemann-Pick disease type C (NP-C) since 2009. The aim of this observational study was to assess the effect of miglustat on long-term survival of patients with NP-C. Data for 789 patients from five large national cohorts and from the NPC Registry were collected and combined. Miglustat-treated and untreated patients overall and within sub-groups according to age-at-neurological-onset, that is, early infantile-onset (<2 years), late infantile-onset (2 to <6 years), juvenile-onset (6 to <15 years), and adolescent/adult-onset (≥15 years) were analysed and compared. Survival was analysed from the time of first neurological manifestation (Neurological onset group, comprising 669 patients) and from diagnosis (Diagnosis group, comprising 590 patients) using a Cox proportional hazard model adjusted for various covariates. Overall, 384 (57.4%) patients in the Neurological onset group and 329 (55.8%) in the Diagnosis group were treated with miglustat. Miglustat treatment was associated with a significant reduction in risk of mortality in both groups (entire Neurological onset group, Hazard ratio [HR] = 0.51; entire Diagnosis group, HR = 0.44; both P < .001). The effect was observed consistently in all age-at-neurological-onset sub-groups (HRs = 0.3 to 0.7) and was statistically significant for late infantile-onset patients in both groups (Neurological onset group, HR = 0.36, P < .05; Diagnosis group, HR = 0.32, P < .01), and juvenile-onset patients in the Diagnosis group only (HR = 0.30, P < .05). Despite the limitations of the data that urge cautious interpretation, the findings are consistent with a beneficial effect of miglustat on survival in patients with NP-C.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22004859
003      
CZ-PrNML
005      
20220127144903.0
007      
ta
008      
220113s2020 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/jimd.12245 $2 doi
035    __
$a (PubMed)32324281
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Patterson, Marc C $u Division of Child and Adolescent Neurology, Departments of Neurology, Pediatrics and Medical Genetics, Mayo Clinic, Rochester, Minnesota, USA
245    10
$a Long-term survival outcomes of patients with Niemann-Pick disease type C receiving miglustat treatment: A large retrospective observational study / $c MC. Patterson, WS. Garver, R. Giugliani, J. Imrie, H. Jahnova, FJ. Meaney, Y. Nadjar, MT. Vanier, P. Moneuse, O. Morand, D. Rosenberg, B. Schwierin, B. Héron
520    9_
$a Miglustat has been indicated for the treatment of Niemann-Pick disease type C (NP-C) since 2009. The aim of this observational study was to assess the effect of miglustat on long-term survival of patients with NP-C. Data for 789 patients from five large national cohorts and from the NPC Registry were collected and combined. Miglustat-treated and untreated patients overall and within sub-groups according to age-at-neurological-onset, that is, early infantile-onset (<2 years), late infantile-onset (2 to <6 years), juvenile-onset (6 to <15 years), and adolescent/adult-onset (≥15 years) were analysed and compared. Survival was analysed from the time of first neurological manifestation (Neurological onset group, comprising 669 patients) and from diagnosis (Diagnosis group, comprising 590 patients) using a Cox proportional hazard model adjusted for various covariates. Overall, 384 (57.4%) patients in the Neurological onset group and 329 (55.8%) in the Diagnosis group were treated with miglustat. Miglustat treatment was associated with a significant reduction in risk of mortality in both groups (entire Neurological onset group, Hazard ratio [HR] = 0.51; entire Diagnosis group, HR = 0.44; both P < .001). The effect was observed consistently in all age-at-neurological-onset sub-groups (HRs = 0.3 to 0.7) and was statistically significant for late infantile-onset patients in both groups (Neurological onset group, HR = 0.36, P < .05; Diagnosis group, HR = 0.32, P < .01), and juvenile-onset patients in the Diagnosis group only (HR = 0.30, P < .05). Despite the limitations of the data that urge cautious interpretation, the findings are consistent with a beneficial effect of miglustat on survival in patients with NP-C.
650    _2
$a 1-deoxynojirimycin $x analogy a deriváty $x terapeutické užití $7 D017485
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a dítě $7 D002648
650    _2
$a předškolní dítě $7 D002675
650    _2
$a inhibitory enzymů $7 D004791
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a kojenec $7 D007223
650    _2
$a novorozenec $7 D007231
650    _2
$a internacionalita $7 D038622
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a Niemannova-Pickova nemoc typu C $x farmakoterapie $x mortalita $7 D052556
650    _2
$a registrace $7 D012042
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a analýza přežití $7 D016019
650    _2
$a výsledek terapie $7 D016896
650    _2
$a mladý dospělý $7 D055815
655    _2
$a časopisecké články $7 D016428
655    _2
$a pozorovací studie $7 D064888
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Garver, William S $u Department of Chemistry and Chemical Biology, University of New Mexico, Albuquerque, New Mexico, USA
700    1_
$a Giugliani, Robert $u Medical Genetics Service, Porto Alegre, Brazil $u Department of Genetics, UFRGS, Porto Alegre, Brazil
700    1_
$a Imrie, Jackie $u Niemann-Pick UK, Washington, UK
700    1_
$a Jahnova, Helena $u Department of Institute of Inherited Metabolic Disorders, Charles University, Prague, Czech Republic
700    1_
$a Meaney, F John $u Department of Pediatrics, University of Arizona, Tucson, Arizona, USA
700    1_
$a Nadjar, Yann $u Department of Neurology, Reference Center for Lysosomal Diseases (CRML), Hôpital de la Pitié-Salpêtrière, Paris, France
700    1_
$a Vanier, Marie T $u INSERM, Lyon, France $u Hopitaux de Lyon, Lyon, France
700    1_
$a Moneuse, Patrick $u Global Business and Science Affairs, Actelion Pharmaceuticals Ltd., Allschwil, Switzerland
700    1_
$a Morand, Olivier $u Global Business and Science Affairs, Actelion Pharmaceuticals Ltd., Allschwil, Switzerland
700    1_
$a Rosenberg, Daniel $u Epidemiology and Observational Studies, Actelion Pharmaceuticals Ltd., Allschwil, Switzerland
700    1_
$a Schwierin, Barbara $u Azafaros B.V, Leiden, The Netherlands $u Sorbonne Universite, Paris, France
700    1_
$a Héron, Benedicte $u Idorsia Pharmaceuticals Ltd., Allschwil, Switzerland $u Department of Neuropediatrics, CRML, Hopital Armand-Trousseau, Paris, France
773    0_
$w MED00002747 $t Journal of inherited metabolic disease $x 1573-2665 $g Roč. 43, č. 5 (2020), s. 1060-1069
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32324281 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220113 $b ABA008
991    __
$a 20220127144859 $b ABA008
999    __
$a ok $b bmc $g 1752154 $s 1156008
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 43 $c 5 $d 1060-1069 $e 20200508 $i 1573-2665 $m Journal of inherited metabolic disease $n J Inherit Metab Dis $x MED00002747
LZP    __
$a Pubmed-20220113

Najít záznam

Citační ukazatele

Možnosti archivace